We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Comment & Response |

Efficacy of the Priority Review Voucher Program

Ameet Sarpatwari, JD, PhD1; Aaron S. Kesselheim, MD, JD, MPH1
[+] Author Affiliations
1Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital, Boston, Massachusetts
JAMA. 2016;315(15):1660-1661. doi:10.1001/jama.2016.0386.
Text Size: A A A
Published online


In Reply We agree with Dr Ridley and colleagues that greater funding for the NIH is important to the discovery of transformative new treatments for tropical diseases.1 Indeed, substantial gains can be made with remarkably little up-front investment. For example, the Drugs for Neglected Diseases Initiative, which has been in existence only a few years longer than the tropical disease priority review voucher program, has spearheaded the development of 6 treatments (and early-stage testing of 12 new chemical entities) for patients with malaria, trypanosomiasis, visceral leishmaniasis, and Chagas disease at a total cost of around $250 million.2


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview




April 19, 2016
David B. Ridley, PhD; Jennifer Dent, MBA; Christopher Egerton-Warburton, MA
1Duke University, Durham, North Carolina
2BIO Ventures for Global Health, Seattle, Washington
3Lion’s Head Global Partners, London, United Kingdom
JAMA. 2016;315(15):1659-1660. doi:10.1001/jama.2016.0377.
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...